AbbVie to Acquire Apogee for $10.9B, a 49% Premium
AbbVie (ABBV) announced the acquisition of Apogee Therapeutics for $135.11 per share in cash, a 49% premium over the last closing price. The deal is valued at approximately $10.9 billion and is expected to close in the first half of 2026.
Key Numbers
AbbVie (ABBV) announced it will acquire Apogee Therapeutics for $135.11 per share in cash, representing a 49% premium over the last closing price. The total deal value is approximately $10.9 billion, and it is expected to close in the first half of 2026.
Deal Details
| Item | Detail |
|---|---|
| Total Value | $10.9 billion |
| Offer Price | $135.11 per share cash |
| Premium | 49% over last close |
| Payment Method | All cash |
| Expected Close | First half of 2026 |
Rationale
AbbVie aims to strengthen its pipeline in inflammatory and immunology diseases through this acquisition. Apogee has promising drug candidates in this area. The deal is part of a broader pharma M&A wave exceeding $200 billion over the past two years.
Regulatory Challenges
The deal is subject to antitrust review in the U.S. and Europe. Given limited product overlap, it is expected to receive regulatory approval without major conditions.
Impact on Stocks
The acquisition is expected to be slightly accretive to AbbVie's EPS in the long term, but may pressure free cash flow in the near term. Regeneron (REGN) stock was not directly affected, but the deal reinforces the sector's focus on immunology therapies.
Frequently Asked Questions
Found this useful? Share it